Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Favorable Immune Reconstitution After Nonmyeloablative, T-Cell Replete, HLA-Haploidentical BMT with Post-Transplant Cyclophosphamide

Heather J. Symons, Chimene Kesserwan, MD, Ferdynand Kos, PhD, Christopher J. Thoburn, MsC, Ashley T. Munchel, MD, Wendy Ying, BA, Leo Luznik, Hyam I. Levitsky, MD, Richard J. Jones, MD, Allan D. Hess, PhD, Ephraim J. Fuchs

Blood (2011) 118 (21): 1009.

https://doi.org/10.1182/blood.V118.21.1009.1009

Published: 2011

Journal Articles

High-Dose Cyclophosphamide (Cy), Rituximab, and a Cancer Vaccine for Relapsed Classical Hodgkin's Lymphoma (cHL)

Yvette L. Kasamon, Richard J. Jones, Hyam I. Levitsky, Ivan M. Borrello, M. Victor Lemas, Michael J. Borowitz, Javier Bolaños-Meade, Lode J. Swinnen, Richard F. Ambinder

Blood (2010) 116 (21): 3954.

https://doi.org/10.1182/blood.V116.21.3954.3954

Published: 2010

Journal Articles

K562/GM-CSF Immunotherapy as a “Booster” Vaccine In Chronic Myeloid Leukemia

Eunpi Cho, M.D., Hyam I. Levitsky, Jeanne Kowalski, PhD, Hua-Ling Tsai, MS, Lu Qin, Research, A, Christopher Gocke, B. Douglas Smith, MD

Blood (2010) 116 (21): 4347.

https://doi.org/10.1182/blood.V116.21.4347.4347

Published: 2010

Journal Articles

High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease

Leo Luznik, Javier Bolaños-Meade, Marianna Zahurak, Allen R. Chen, B. Douglas Smith, Robert Brodsky, Carol Ann Huff, Ivan Borrello, William Matsui, Jonathan D. Powell, Yvette Kasamon, Steven N. Goodman, Allan Hess, Hyam I. Levitsky, Richard F. Ambinder, Richard J. Jones, Ephraim J. Fuchs

Blood (2010) 115 (16): 3224–3230.

https://doi.org/10.1182/blood-2009-11-251595

Published: 2010

Journal Articles

Granulocyte-macrophage colony-stimulating factor (GM-CSF)–secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML)

Ivan M. Borrello, Hyam I. Levitsky, Wendy Stock, Dorie Sher, Lu Qin, Daniel J. DeAngelo, Edwin P. Alyea, Richard M. Stone, Lloyd E. Damon, Charles A. Linker, Daniel J. Maslyar, Kristen M. Hege

Blood (2009) 114 (9): 1736–1745.

https://doi.org/10.1182/blood-2009-02-205278

Published: 2009

Includes: Supplemental data

Journal Articles

Escape from suppression: tumor-specific effector cells outcompete regulatory T cells following stem-cell transplantation

Paria Mirmonsef, Gladys Tan, Gang Zhou, Tricia Morino, Kimberly Noonan, Ivan Borrello, Hyam I. Levitsky

Blood (2008) 111 (4): 2112–2121.

https://doi.org/10.1182/blood-2007-06-096586

Published: 2008

Journal Articles

Characterization of Immune Reconstitution Following High Dose Chemotherapy in Acute Myeloid Leukemia.

Christian F. Meyer, MD, PhD, Christopher Thoburn, Ferdynand Kos, PhD, Christopher Gocke, MD, Hyam I. Levitsky, MD, Janet A. Briel, Allan Hess, PhD, Judith E. Karp, MD

Blood (2007) 110 (11): 3888.

https://doi.org/10.1182/blood.V110.11.3888.3888

Published: 2007

Journal Articles

Ex Vivo Fas Ligand Treatment Selectively Eliminates T Cells That Mediate GVHD.

Osnat Kashtan, PhD, Hyam I. Levitsky, MD, Curt I. Civin, MD

Blood (2006) 108 (11): 3167.

https://doi.org/10.1182/blood.V108.11.3167.3167

Published: 2006

Journal Articles

Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines

Gang Zhou, Charles G. Drake, Hyam I. Levitsky

Blood (2006) 107 (2): 628–636.

https://doi.org/10.1182/blood-2005-07-2737

Published: 2006

Journal Articles

K562/GM-CSF Vaccination Reduces Tumor Burden, Including Achieving Molecular Remissions, in Chronic Myeloid Leukemia (CML) Patients with Residual Disease on Imatinib Mesylate (IM).

B. Douglas Smith, MD, Yvette L. Kasamon, MD, Carole B. Miller, MD, Christina Chia, MD, Kathleen Murphy, PhD, Jeanne Kowalski, PhD, Irena Tartakovsky, MS, Barbara Biedrzycki, AOCN/CRNP, Richard J. Jones, MD, Kristen Hege, MD, Hyam I. Levitsky, MD

Blood (2005) 106 (11): 2858.

https://doi.org/10.1182/blood.V106.11.2858.2858

Published: 2005

Journal Articles

Posttransplant Immunotherapy with a GM-CSF-Based Tumor Vaccine (GVAX®) Following Autologous Stem Cell Transplant (ASCT) for Acute Myeloid Leukemia (AML).

Daniel J. DeAngelo, Edwin P. Alyea, Ivan M. Borrello, Hyam I. Levitsky, Wendy Stock, Dorie Sher, Lloyd E. Damon, Charles A. Linker, Amy Donnelly, Kristen M. Hege

Blood (2004) 104 (11): 441.

https://doi.org/10.1182/blood.V104.11.441.441

Published: 2004

Journal Articles

Successful therapy of metastatic cancer using tumor vaccines in mixed allogeneic bone marrow chimeras

Leo Luznik, Jill E. Slansky, Sanju Jalla, Ivan Borrello, Hyam I. Levitsky, Drew M. Pardoll, Ephraim J. Fuchs

Blood (2003) 101 (4): 1645–1652.

https://doi.org/10.1182/blood-2002-07-2233

Published: 2003

Journal Articles

Cross-presentation of tumor antigens by bone marrow–derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression

Eduardo M. Sotomayor, Ivan Borrello, Frédérique-Marie Rattis, Alex G. Cuenca, Jacob Abrams, Kevin Staveley-O'Carroll, Hyam I. Levitsky

Blood (2001) 98 (4): 1070–1077.

https://doi.org/10.1182/blood.V98.4.1070

Published: 2001

Journal Articles

When magic bullets miss their mark

Hyam I. Levitsky

Blood (2001) 97 (4): 833.

https://doi.org/10.1182/blood.V97.4.833

Published: 2001

Journal Articles

Sustaining the graft-versus-tumor effect through posttransplant immunization with granulocyte-macrophage colony-stimulating factor (GM-CSF)–producing tumor vaccines

Ivan Borrello, Eduardo M. Sotomayor, Frédérique-Marie Rattis, Sara K. Cooke, Lingping Gu, Hyam I. Levitsky

Blood (2000) 95 (10): 3011–3019.

https://doi.org/10.1182/blood.V95.10.3011

Published: 2000

NARROW

Favorable Immune Reconstitution After Nonmyeloablative, T-Cell Replete, HLA-Haploidentical BMT with Post-Transplant Cyclophosphamide

High-Dose Cyclophosphamide (Cy), Rituximab, and a Cancer Vaccine for Relapsed Classical Hodgkin's Lymphoma (cHL)

K562/GM-CSF Immunotherapy as a “Booster” Vaccine In Chronic Myeloid Leukemia

High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease

Granulocyte-macrophage colony-stimulating factor (GM-CSF)–secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML)

Escape from suppression: tumor-specific effector cells outcompete regulatory T cells following stem-cell transplantation

Characterization of Immune Reconstitution Following High Dose Chemotherapy in Acute Myeloid Leukemia.

Ex Vivo Fas Ligand Treatment Selectively Eliminates T Cells That Mediate GVHD.

Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines

K562/GM-CSF Vaccination Reduces Tumor Burden, Including Achieving Molecular Remissions, in Chronic Myeloid Leukemia (CML) Patients with Residual Disease on Imatinib Mesylate (IM).

Posttransplant Immunotherapy with a GM-CSF-Based Tumor Vaccine (GVAX®) Following Autologous Stem Cell Transplant (ASCT) for Acute Myeloid Leukemia (AML).

Successful therapy of metastatic cancer using tumor vaccines in mixed allogeneic bone marrow chimeras

Cross-presentation of tumor antigens by bone marrow–derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression

When magic bullets miss their mark

Sustaining the graft-versus-tumor effect through posttransplant immunization with granulocyte-macrophage colony-stimulating factor (GM-CSF)–producing tumor vaccines

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only